The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Should bispecifics or CAR-T be given first in R/R FL?
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, provides an insight into the debate on whether bispecific antibodies or CAR T-cell therapy should be given as the first immunotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL). In most patients, bispecific antibodies will be the better option initially, as they tend to confer a more favorable safety profile and can be combined with a range of agents to improve treatment efficacy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Takeda, Roche and Genmab, Celgene, Novartis; Consultancy: Takeda, Roche and Genmab, Celgene, Novartis, AbbVie, AstraZeneca, Janssen, Merck, F. Hoffmann-La Roche Ltd, Bristol Myers-Squibb, Genentech, Incyte; Honoraria: Takeda, Roche and Genmab, Celgene, AbbVie, AstraZeneca, Merck, F. Hoffmann-La Roche Ltd; Membership on an Entity’s Board of Directors or Advisory Committees: Takeda, Roche and Genmab, Celgene, AbbVie, AstraZeneca, Janssen, Merck, F. Hoffmann-La Roche Ltd.
